Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Werewolf Therapeutics is raising $56,172,597.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Daniel Hicklin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Werewolf Therapeutics

At Werewolf Therapeutics, we are unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. Under precise conditions, our technology allows us to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues ultimately delivering a more clinically meaningful impact for patients. Our goal is to vastly improve the lives of a broad range of people living with cancer.

To learn more about Werewolf Therapeutics, visit http://werewolftx.com/

Contact:
Daniel Hicklin, President and Chief Executive Officer
617-952-0555

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved